May 012014

The Hygiology Post ®  is presenting information about a company that seems to have much potential to help many people. The years 2012, 2013, and 2014 do appear to likely be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site. As a matter of disclosure : The author continues to be a current shareholder in the company.

An article posted on the Senesco Technologies web site recently (; obtained on 4-30-14) began the following way:


Senesco Announces Presentation on the Effectiveness of eIF5A in Inhibiting Tumor Progression in Liver Cancer Models Presentation at 17th Annual Meeting of American Society of Gene & Cell Therapy

BRIDGEWATER, N.J. (April 28, 2014) – Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (OTC QB: SNTI), announced today that an oral presentation will be delivered on its potential approach to treating hepatocellular carcinoma at the 17th Annual Meeting of the American Society of Gene & Cell Therapy during the session entitled ‘Cancer-Targeted Gene & Cell Therapy II’.

The conference will be held May 21-24, 2014 at the Marriott Wardman Park in Washington, DC. The presentation entitled ‘An eIF5A-based gene therapy nanoparticle induces apoptosis and inhibits hepatocellular carcinoma tumour progression in both xenograft and orthotopic models’, will be delivered at 12 noon on Saturday May 24 by Dr. Sarah Francis, who is a member of Senesco CSO John E. Thompson’s research laboratory at the University of Waterloo in Ontario, Canada. The abstract for the presentation may be viewed at”

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.  © 2014                                    The Hygiology Post ®